New nucleoside analogs in the treatment of solid tumors

Acta Poloniae Pharmaceutica - Drug Research

Volumn 61, Issue 4, 2004, Pages 297-305

  Szafraniec, Sylwia I ^a   Stachnik, Krzysztof J ^a   Skierski, Janusz S ^a  

^a NATIONAL MEDICINES INSTITUTE   (Poland)

Author keywords

Clofarabine; CNDAC; Decitabine; DMDC; ECyD; Nucleoside analogs; Solid tumors; Tezacitabine; Troxacitabine

Indexed keywords

2' C CYANO 2' DEOXY 1 BETA DEXTRO ARABINOPENTOFURANOSYLCYTOSINE; 2' DEOXY 2' METHYLIDENECYTIDINE; 3' ETHYNYLCYTIDINE; 3' ETHYNYLOCYTIDINE; 5 AZA 2' DEOXYCYTIDINE; CISPLATIN; CLOFARABINE; CYTARABINE; DEOXYRIBONUCLEOTIDE; FLUOROURACIL; GEMCITABINE; NUCLEOSIDE; NUCLEOSIDE ANALOG; OXALIPLATIN; TEZACITABINE; TOPOTECAN; TROXACITABINE; UNCLASSIFIED DRUG; VINBLASTINE;

ADVANCED CANCER; ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD TOXICITY; BOLUS INJECTION; BONE MARROW SUPPRESSION; BONE METASTASIS; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; CYTOSTASIS; CYTOTOXICITY; DNA METHYLATION; DNA REPLICATION; DNA SYNTHESIS; DOSE RESPONSE; DRUG ELIMINATION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; ESOPHAGUS CANCER; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL TUMOR; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HUMAN; INFUSION; KIDNEY CARCINOMA; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; RASH; RNA SYNTHESIS; SIGNAL TRANSDUCTION; SOLID TUMOR; STATISTICAL SIGNIFICANCE; STOMACH CANCER; THROMBOCYTOPENIA;

ADENINE NUCLEOTIDES; ANIMALS; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; AZACITIDINE; CLINICAL TRIALS; CYTARABINE; CYTIDINE; CYTOSINE; DEOXYCYTIDINE; DIOXOLANES; HUMANS; NEOPLASMS; NUCLEOSIDES;

EID: 13244278170     PISSN: 00016837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (93)

1. Wagstaff A.J, Ibbotson T., Goa K.L.: Drugs 63(2),217 (2003).
2. Ward S, Kaltenthaler E, Cowan J, Brewer N.: Health Technol. Assess. 7(32),1 (2003).
3. Galmarini C.M, Jordheim L, Dumontet C.: Exp. Rev. of Anticancer Ther. 3(5),717 (2003).
4. Faderl S, Gandhi V, Kantarjian H, Plunkett W.: Cancer Chemother. Biol. Response Modif. 20,37 (2002).
5. Szafraniec S.I, Stachnik K., Skierski J.S.: Acta Pol. Pharm. (2004) (in press).
6. McCarthy J.R, Sunkara P.S.: in Weiner D.M, Williams W.B Eds., p. 3, CRC Press, Boca Raton, FL 1995.
7. Takahashi T, Nakashima A, Kanazawa: J. Cancer Chemother. Pharmacol. 41,268 (1998).
8. Woessner R.D, Loudy D.E, Wallace C.D, Montgomery L.R.: Oncol. Res. 9,543 (1997).
9. Skierski J.S.: Biuletyn Instytutu Leków 46(3-4),341 (2002).
10. Skierski J.S, Koronkiewicz M, Grieb P.: Cytometry 37(4),302 (1999).
11. Skierski J.S, Koronkiewicz M, Grieb P.: Cell Cycle (2004) (in press).
12. Piepmeier J.M, Rabidou N, Schold S.C Jr, Bitonti A.J, Prakash N.J, Bush T.L.: Cancer Res. 56(2),359 (1996).
13. Kotchetkov R, Krivtchik A.A, Cinatl J, Kornhuber B, Cinatl J Jr.: Folia Biol. (Praha) 45(5),185 (1999).
14. Grieb P, Koronkiewicz M, Skierski J.S.: Acta Biochim. Pol. 47(1),165 (2000).
15. Snyder R.D.: Oncol. Res. 6(4-5),177 (1994).
16. Sun L.Q, Li Y.X, Guillou L, Coucke P.A.: Cancer Res. 58,5411 (1998).
17. Coucke P.A, Decosterd L.A, Li Y.X.: Cancer Res. 59,5219 (1999).
18. Rodriguez G.I, Jones R.E, Orenberg E.K, Stoltz M.L, Brooks D.J.: Clin. Cancer Res. 8(9),2828 (2002).
19. Burtness B, Belker M, Stoltz M, Peccerillo K.M, Lamb L.A, Chmael S.E, McKeon A, Clark M.B, Winship J, Marsh J.C, Pizzorno G, DeVita V.T. Jr.: Cancer J. 6(5),309 (2000).
20. Masuda N, Negoro S, Takeda K, Takifuji N, Hirashima T, Yana T, Kurata N, Kuwabara T, Kobayashi S, Kudoh S, Matsui K, Takada M, Fukuoka M.: Invest. New Drugs 16(3),245 (1999).
21. Flaherty K.T, Stevenson J.P, Gallagher M, Giantonio B, Algazy K.M, Sun W, Haller D.G, O'Dwyer P.J.: Cancer 97(8),985 (2003).
22. Brooks D.J., Cox J., Berman B.S.: Proc. Am. Soc. Clin. Oncol. 22 (Abstr. 1122), p.279 (2003).
23. Grove K, Guo X, Liu S, Gao Z.: Cancer Res. 55,3008 (1995).
24. Chou K.M, Kukhanova M, Cheng Y.C.: J. Biol. Chem. 275(40),31009 (2000).
25. Plunkett W, Gandhi V.: Can. Chem. Biol. Res. Mod. 19,21 (2001).
26. Gourdeau H, Genne P, Kadhim S, Bibeau L, Duchamp O, Ouellet F, deMuys JM, Bouffard DY, Attardo G.: Cancer Chemother. Pharmacol. 50(6),490 (2002).
27. Grove K, Cheng Y.: Cancer Res. 56,4187 (1996).
28. Weitman S, Marty J, Jolivet J, Locas C, Von Hoff D.: Clin. Cancer Res. 6,1574 (2000).
29. Rabbani S.A, Harakidas P, Bowlin T, Attardo G.: Cancer Res. 58(15),3461 (1998).
30. de Bono J.S, Stephenson J. Jr, Baker S.D, Hidalgo M, Patnaik A, Hammond L.A, Weiss G, Goetz A, Siu L, Simmons C, Jolivet J, Rowinsky EX.: J. Clin. Oncol. 20(1),96 (2002).
31. Belanger K., Moore M., Baker S.D., Dionne J., Maclean M., Jolivet J., Siu L., Soulieres D., Wainman N., and Seymour L.: J. Clin. Oncol. 20(10),2567 (2002).
32. Canova A, Yee L, Baker S, Sarid R, Desforges C, Jolivet J.: Proc. Am. Soc. Clin. Oncol. 18,197a (1999).
33. Baker S.D, Stephenson J, Goetz A, Belanger K.: Proc. Am. Soc. Clin. Oncol. 18,197a (1999).
34. Patnaik A, Goetz A.D, Denis L, Hao D, Rha S.Y, Forouzesh B, de Bono J.: Proc. Am. Soc. Clin. Oncol. 20,363 (2001).
35. Lapointe R, Letourneau R, Steward R.: Proc. Am. Soc. Clin. Oncol. 21,565 (2002).
36. Townsley C.A, Chi K, Ernst D.S, Belanger K, Tannock I, Bjarnason G.A, Stewart D, Goel R, Ruether J.D, Siu L.L, Jolivet J, McIntosh L, Seymour L, Moore M.J.: J. Clin. Oncol. 21(8),1524 (2003).
37. Adis International Ltd.: Drugs R D. 4(4),264 (2003).
38. Matsuda A, Azuma A, Nakajima Y, Takenuki K, Dan A, Iino T, Yoshimura Y, Minakawa N, Tanaka M, Sasaki T.: in C. K. Chu and D. C. Baker Eds., Nucleosides and Nucleotides As Antitumor Antiviral Agents, p.1, New York, Plenum Press, 1993.
39. Ono T.: Biochem. Pharmacol. 52,1279 (1996).
40. Elford H, Freese M, Passamani E, Morris H.: J. Biol. Chem. 245,5228 (1970).
41. Bouffard D.Y, Laliberte J, Momparler R.L.: Biochem. Pharmacol. 45,1857 (1993).
42. Miwa M, Eda H, Ura M, Ouchi K, Keith D.D, Foley L.H, Ishitsuka H. Clin.: Cancer Res. 493 (1998).
43. Eda H, Ura M, Ouchi K, Tanaka Y, Miwa M, Ishitsuka H.: Cancer Res. 58,1165 (1998).
44. Yamagami K, Fujii A, Arita M, Okamoto T, Sakata S, Matsuda A, Ueda T, Sasaki T.: Cancer Res. 51,2319 (1991).
45. Gemma A, Kudoh S, Fukuoka M, Kurita Y, Hasegawa K. Gan To Kagaku Ryoho. 23(13), 1799 (1996) (in japanese).
46. Noriyuki M, Kaoru M, Nobuyuki Y.: Clin. Cancer Res. 6,2288 (2000).
47. Friberg L.E, Brindley C.J, Karlsson M.O, Devlin A.J.: Eur. J. Clin. Pharmacol. 56(8),567 (2000).
48. Azuma A, Nakajima Y, Nishizono N.: J. Med. Chem. 36,4183 (1993).
49. Hayakawa Y, Kawai R, Otsuki K, Kataoka M, Matsuda A.: Bioorg Med. Chem. Lett. 8,2559 (1998).
50. Matsuda A, Azuma A.: Nucleosides Nucleotides. 14,461 (1995).
51. Hanaoka K, Suzuki M, Kobayashi T.: Int. J. Cancer. 82,226 (1999).
52. Azuma A, Huang P, Matsuda A, Plunkett W.: Mol. Pharmacol. 59(4),725 (2001).
53. Tanaka M, Matsuda A, Terao T, Sasaki T.: Cancer Lett. 64,67 (1992).
54. Hanaoka K, Suzuki M, Kobayashi T, Tanazawa F, Tanaka K.: Int. J. Cancer. 82,226 (1999).
55. Asai T, Shimizu K, Kondo M, Kuromi K, Watanabe K, Ogino K, Taki T, Shuto S, Matsuda A, Oku N.: FEBS Lett. 520(1-3),167 (2002).
56. Asai T, Shuto S, Matsuda A, Kakiuchi T, Ohba H, Tsukada H, Oku N.: Cancer Lett. 162(1),49 (2001).
57. Asai T, Shimizu K, Kondo M, Kuromi K, Watanabe K, Ogino K, Taki T, Shuto S, Matsuda A, Oku N.: FEBS Lett. 520(1-3),167 (2002).
58. Donehower R.C, Dees E.C, Baker S.D.: Proc. Am. Soc. Clin. Oncol. 19,196a (2000).
59. Burch P.A, Camoriano J.K, Braich T.A.: Proc. Am. Soc. Clin. Oncol. 20,92a (2001).
60. Azuma A, Emura T, Huang P, Plunkett W.: Proc. Am. Assoc. Cancer Res. 40,298 (1999).
61. Shimamoto Y, Fujijoka A, Kazuno H.: Jpn. J. Cancer Res. 92,343 (2001).
62. Faded S, Gandhi V, Kantarjian H, Plunkett W.: Cancer Chemother. Biol. Response Modif. 20,37 (2002).
63. Shimamoto Y, Koizumi K, Okabe H, Kazuno H, Murakami Y, Nakagawa F, Matsuda A, Sasaki T, Fukushima M.: Jpn. J. Cancer Res. 93(7),825 (2002).
64. Shimamoto Y, Fujioka A, Kazuno H, Murakami Y, Ohshimo H, Kato T, Matsuda A, Sasaki T, Fukushima M.: Jpn. J. Cancer Res. 92(3),343 (2001).
65. Xie K.C, Plunkett W.: Cancer Res. 56(13),3030 (1996).
66. Waud W.R, Schmid S.M, Montgomery J.A, Secrist J.A.: Nucleosides Nucleotides Nucleic Acids. 19(1-2),447 (2000).
67. Takahashi T, Kanazawa J, Akinaga S, Tamaoki T, Okabe M.: Cancer Chemother. Pharmacol. 43(3),233 (1999).
68. Kantarjian H.M, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, O'Brien S, Ibrahim N, Khuri F, Du M, Rios MB, Jeha S, McLaughlin P, Plunkett W, Keating M.: J. Clin. Oncol. 21(6),1167 (2003).
69. Santini V, Kantarjian H.M, Issa J.P.: Ann. Intern. Med. 134(7),573 (2001).
70. Palmisano W.A, Crume K.P, Grimes M.J, Winters S.A, Toyota M, Esteller M, Joste N, Baylin S.B, Belinsky S.A.: Cancer Res. 63(15),4620 (2003).
71. Bender C.M, Zingg J.M, Jones P.A.: Pharm. Res. Feb. 15(2),175 (1998).
72. Velden P.A, Zuidervaart W, Hurks M.H, Pavey S, Ksander B.R, Krijgsman E, Frants R.R, Tensen C.P, Willemze R, Jager M.J, Gruis N.A.: Int. J. Cancer. 106(4),472 (2003).
73. Karpf A.R, Moore B.C, Ririe T.O, Jones D.A.: Mol. Pharmacol. 59(4),751 (2001).
74. Koshy M, Dorn L, Bressler L, Molokie R, Lavelle D, Talischy N, Hoffman R, van Overveld W.: Blood 96(7),2379 (2000).
75. DeSimone J, Koshy M, Dorn L, Lavelle D, Bressler L, Molokie R, Talischy N.: Blood 99(11),3905 (2002).
76. Saunthararajah Y, Hillery C.A, Lavelle D, Molokie R, Dorn L, Bressler L, Gavazova S, Chen Y.H, Hoffman R, DeSimone J.: Blood 102(12),3865 (2003).
77. Yuan J, Luo R.Z, Fujii S, Wang L, Hu W, Andreeff M, Pan Y, Kadota M, Oshimura M, Sahin A.A, Issa J.P, Bast R.C, Yu Y.: Cancer Res. 63(14),4174 (2003).
78. Bender C.M, Pao M.M, Jones P.A.: Cancer Res. 58(1),95 (1998).
79. Ferguson A.T, Vertino P.M, Spitzner J.R, Baylin S.B, Muller M.T, Davidson N.E.: J. Biol. Chem. 272(51),32260 (1997).
80. Lavelle D, DeSimone J, Hankewych M, Kousnetzova T, Chen Y.H.: Leuk. Res. 27(11),999 (2003).
81. Gattei V, Aldinucci D, Petti M.C, Da Ponte A, Zagonel V, Pinto A., Leukemia (Suppl. 7) 1,42 (1993).
82. Lantry L.E, Zhang Z, Crist K.A.: Carcinogenesis 20,343 (1999).
83. Laird P.W, Jackson-Grusby L., Fazeli A.: Cell 81,197 (1995).
84. Anzai H, Frost P, Abbruzzese J.L.: Cancer Res. 52(8),2180 (1992).
85. Abbruzzese J.L, Frost P.: Cancer Chemother. Pharmacol. 30(1),31 (1992).
86. Aparicio A, Eads C.A, Leong L.A.: Cancer Chemother. Pharmacol. 51(3),231 (2003).
87. Pohlmann P, DiLeone L.P, Cancella A.I.: Am. J. Clin. Oncol. 25(5),496 (2002).
88. Schwartsmann G, Schunemann H, Gorini C.N.: Invest. New. Drugs. Feb. 18(1),83 (2000).
89. Groenigen C.J, Leyva A, O'Brien A.M.: Cancer Res. 46(9),4831 (1986).
90. Weiss A.J, Mastrangelo M.J, Laucius J.F, Bellet R.E.: Cancer Chemother. Rep. 56,413 (1972).
91. Cunningham T.J, Nemoto T, Rosner D, Knight E.: Cancer Chemother. Rep. 58,677 (1974).
92. Weiss A.J, Metter G.E, Nealon T.F.: Cancer Treat Rep.61:55 (1977).
93. Momparler R.L, Bouffard D.Y, Momparler L.F.: Anticancer Drugs. 8,358 (1997).